A major new biotech manufacturing facility will be established in Melbourne, helping to position Victoria at the forefront of the global influenza vaccine market.

Seqirus, a subsidiary of Victorian-based global biopharmaceutical leader CSL, will invest more than $800 million to build the state-of-the-art facility at the Melbourne Airport Business Park, with operations expected to start in 2026.

Seqirus CSL Biomedical Manufacturing Facility

The only cell-based influenza vaccine manufacturing facility in the southern hemisphere, the facility will also produce other life-saving products for the Australian market such as the world’s only Q-Fever vaccine and anti-venom for local snakes, spiders and marine creatures.

An agreement between the Commonwealth Government and Seqirus has secured the supply of these products and influenza pandemic protection for Australia over the next 10 years.

The new facility will produce seasonal influenza vaccines for use globally and have the capacity to rapidly scale up vaccine production in response to any future influenza pandemic and guarantee the nation with a priority supply.

Headquartered in Melbourne since its inception in 1916, CSL is one of the world’s leading biotech companies and continues to invest in Victoria due to the quality of the state’s infrastructure, universities and workforce.

Victoria’s medical research institutes employ more than 4,800 people. The state’s wider medical research sector supports more than 30,000 jobs across institutes, universities and industry.

Contact us to explore opportunities for investing Victoria’s world class medical research industry.